Indeed, our de novo somatic indel calling from TCGA RNA-seq increases the TCGA driver indel repertoire by ∼14%, especially in samples with purity less than 0.4, including actionable <i>EGFR</i> indels in lung adenocarcinoma and <i>FLT3</i> in acute myeloid leukemia. This evidence concerns the gene EGFR and acute myeloid leukemia.